ESC Premium Access

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Congress Session

About the speaker

Doctor Abdul Shokor Parwani

Charite - Campus Virchow-Klinikum (CVK), Berlin (Germany)
1 presentation
0 follower

24 more presentations in this session

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

Speaker: Professor D. Xavier (Bangalore, IN)

Thumbnail

Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers

Speaker: Doctor C. Gatti (Ravenna, IT)

Thumbnail

High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

Speaker: Doctor D. Iglesias (Santiago de Compostela, ES)

Thumbnail

CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation

Speaker: Doctor J. Wieczorek (Katowice, PL)

Thumbnail

Recalibration of CHA2DS2-VASc with an age category (50-64 years) enhances stroke risk stratification in chinese patients with atrial fibrillation

Speaker: Doctor P. Chan (London, GB)

Thumbnail

Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation III

Speakers: Doctor A. Parwani, Professor D. Xavier, Doctor C. Gatti, Doctor D. Iglesias, Doctor J. Wieczorek...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk